Bioavailability and cardiovascular safety of dexatrim® (phenylpropanolamine hydrochloride) from a controlledrelease caplet
Authors:
- 1 October 1990
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 11 (7) , 569-583
Abstract
The bioavailability and pharmacokinetics of phenylpropanolamine hydrochloride (PPA HCl) from a Dexatrim® controlled‐release (CR) caplet and solution was studied. Each subject (n = 12) received either a 75 mg PPA HCl CR caplet once daily or a 25 mg PPA HCl solution given three times a day. All subjects received the medication for 4 consecutive days. On Day 1, the mean ± SEM, AUC, tmax, and Cmax values were 1651 ± 127 ng x h ml−1, 4·5 ± 0·26 h and 143 ± 13·5 ng ml−1, respectively, for the CR caplet and 1716 ± 90·3ng × h ml−1, 1·25 ± 0·08 h and 126 ± 5·8 ng ml−1 for the solution, respectively. At steady state (Day 4), the mean ± SEM, AUC, tmax, and Cmax values were 1832 ± 101 ng x h ml−1, 4·17 ± 0·17 h and 151 ± 6·5 ng ml−1, respectively, for the CR caplet and 2014 ± 116 ng x h ml−1, 1·33 ± 0·09 h and 143 ± 8·7 ng ml−1, respectively, for the solution. The data from Day 1 were fitted to an oral one compartment model with a first order absorption rate constant, kA, first order elimination rate constant, k and lag time. The mean ± SEM, kA, elimination half‐life and lag time for PPA HCl from the CR caplet were 0·488 ± 0·182 ng h ml−1, 5·84 ± 1·66 h and 0·394 ± 0·224 h, respectively. The mean ± SEM, kA, elimination half‐life and lag time for PPA HCl from the solution were 2·87 ± 1·51 ng x h ml−1, 3·73 ± 1·21 h, and 0·325 ± 0·101 h. respectively. The smaller apparent kA and longer elimination half‐life for PPA HCl from the CR caplet is due to the slow release of PPA HCl, thereby slowing its absorption producing sustained plasma drug concentrations. Blood pressures (supine and sitting) and heart rates measured at the time of blood sampling after the administration of the PPA HCl dosage forms demonstrated no clinically significant relationship between cardiovascular response and PPA HCl plasma concentration. These data demonstrate the bioavailability and pharmacokinetics of PPA HCl from a CR caplet and an immediate release solution.Keywords
This publication has 11 references indexed in Scilit:
- The effects of phenylpropanolamine on human sympathetic nervous system functionNeuropsychopharmacology, 1988
- Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled‐release dosesBiopharmaceutics & Drug Disposition, 1987
- Pharmacokinetics of phenylpropanolamine in humans after a single-dose studyInternational Journal of Pharmaceutics, 1987
- Phenylpropanolamine: Effects on Subjective and Cardiovascular Variables at Recommended Over‐the‐Counter Dose LevelsThe Journal of Clinical Pharmacology, 1987
- The effect of phenylpropanolamine on ambulatory blood pressureClinical Pharmacology & Therapeutics, 1986
- Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modificationClinical Pharmacology & Therapeutics, 1986
- Ion-Pair Liquid Chromatographic Analysis of Phenylpropanolamine in Plasma and Urine by Post-Column Derivatization with O-PhthalaldehydeJournal of Liquid Chromatography, 1985
- Phenylpropanolamine and Blood PressureJAMA, 1985
- Species differences in the metabolism of norephedrine in man, rabbit and ratBiochemical Journal, 1973
- Evaluation of a Sustained Release Form of Phenylpropanolamine Hydrochloride by Urinary Excretion StudiesJournal of Pharmaceutical Sciences, 1961